Phase 4 N=89 Randomized Single-blind Treatment

The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye

Glaucoma · Application Site Pigmentation Changes

Bottom Line

View on ClinicalTrials.gov: NCT00705757 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jan 2016

Primary outcome: Primary: The Extent of Latanoprost, Bimatoprost and Travoprost Induced Periocular Skin Hyperpigmentation Over a One Year Time Course in Newly Diagnosed Primary Open Angle and Ocular Hypertension Patients. — -0.90; -1.42; -0.90; -0.37 L*a*b* — p=0.769

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: latanoprost (Drug); bimatoprost (Drug); travoprost (Drug)
Age: Adult, Older Adult · 30+ yrs
Sex: All
Sponsor: Summa Health System
Primary completion: Apr 2011

Outcome Measures

Outcome	Result	p-value
PRIMARY The Extent of Latanoprost, Bimatoprost and Travoprost Induced Periocular Skin Hyperpigmentation Over a One Year Time Course in Newly Diagnosed Primary Open Angle and Ocular Hypertension Patients.	-0.90; -1.42; -0.90; -0.37; 0.48; 0.17	0.769

Summary

The purpose of this study is to study changes in skin color that may be caused by using one of the three eye medicines: Xalatan, Travatan or Lumigan.

Eligibility Criteria

Inclusion Criteria

patients recently diagnosed with primary open angle glaucoma or ocular hypertension
Caucasian and African American ethnicities
Male and Female
Age 30 and above

Exclusion Criteria

A history of ocular medication use within the last 12 months
Inflammatory/ allergic skin diseases or dermatitis
presence of periocular hyperpigmented skin lesions
Systemic pigmentation disorders
Use of systemic drugs that can affect skin pigmentation
Visitation of tanning salons, or use of self tanning products
Pregnancy or patients planning to become pregnant in the near future

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00705757). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.